Efficacy and safety of propiverine and terazosine combination for one year in male patients with luts and detrusor overactivity

Basit Öğe Kaydı
dc.authoridGOKTUG, Hasan Nedim Goksel/0000-0001-9762-0641
dc.authoridIMAMOGLU, MUHAMMET ABDURRAHIM/0000-0003-3848-7312
dc.authoridSener, Nevzat Can/0000-0003-3974-187X
dc.contributor.authorSener, Nevzat Can
dc.contributor.authorOzturk, Ufuk
dc.contributor.authorGoktug, H. N. Goksel
dc.contributor.authorGucuk, Adnan
dc.contributor.authorNalbant, Ismail
dc.contributor.authorYesil, Suleyman
dc.contributor.authorImamoglu, M. Abdurrahim
dc.date.accessioned2024-09-25T19:58:49Z
dc.date.available2024-09-25T19:58:49Z
dc.date.issued2013
dc.departmentAbant İzzet Baysal Üniversitesien_US
dc.description.abstractPurpose: To evaluate the long term efficacy and safety of the use of propiverine and terazosine combination in patients with LUTS and DO by a placebo controlled study. Materials and Methods: One hundred patients were enrolled in the study. They were randomized into two groups (each group consisted of 50 patients). Terazosine and placebo were administered to the patients in Group 1 and terazosine plus propiverine HCL was administered to Group 2. The patients were evaluated by international prostate symptom score (IPSS), the first four questions of IPSS (IPSS4), the 8th question of IPSS (quality of life-QoL), overactive bladder symptom score questionnaire (OAB-q V8), PSA test, urodynamic studies, post voiding residue (PVR). All patients were followed for one year and were reassessed for comparison. Results: IPSS, IPSS4, OAB symptoms, QoL score, PVR, and Qmax scores of the groups did not differ. After one year treatment, there was significant improvement in IPSS, IPSS4, OAB symptoms, QoL and Qmax values in Group 2. No significant improvement was noted for the same parameters in Group 1. Conclusion: This is the first study to show long term safety and efficacy of anticholinergic therapy for patients with LUTS. In patients with OAB or DO, long term anticholinergic treatment may be regarded as a treatment option.en_US
dc.identifier.doi10.1590/S1677-5538.IBJU.2013.04.09
dc.identifier.endpage518en_US
dc.identifier.issn1677-5538
dc.identifier.issn1677-6119
dc.identifier.issue4en_US
dc.identifier.pmid24054398en_US
dc.identifier.startpage513en_US
dc.identifier.urihttps://doi.org/10.1590/S1677-5538.IBJU.2013.04.09
dc.identifier.urihttps://hdl.handle.net/20.500.12491/13771
dc.identifier.volume39en_US
dc.identifier.wosWOS:000327879200009en_US
dc.identifier.wosqualityQ4en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherBrazilian Soc Urolen_US
dc.relation.ispartofInternational Braz J Urolen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.snmzYK_20240925en_US
dc.subjectLower Urinary Tract Symptomsen_US
dc.subjectProstatic Hyperplasiaen_US
dc.subjectUrinary Bladder, Overactiveen_US
dc.subjectpropiverineen_US
dc.titleEfficacy and safety of propiverine and terazosine combination for one year in male patients with luts and detrusor overactivityen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu